Chemokines and their receptors in respiratory disease: a therapeutic target for respiratory syncytial virus infection
Cell recruitment is a multistep process orchestrated by chemokines and their receptors. The chemokine/receptor system is central to many inflammatory diseases, making it a key target for therapeutic intervention. Despite complexity and redundancy within the system, effective antagonists are in devel...
Gespeichert in:
| Veröffentlicht in: | Expert review of anti-infective therapy 2007-06, Vol.5 (3), p.415-425 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 425 |
|---|---|
| container_issue | 3 |
| container_start_page | 415 |
| container_title | Expert review of anti-infective therapy |
| container_volume | 5 |
| creator | Thomas, Lynette H Friedland, Jon S Sharland, Mike |
| description | Cell recruitment is a multistep process orchestrated by chemokines and their receptors. The chemokine/receptor system is central to many inflammatory diseases, making it a key target for therapeutic intervention. Despite complexity and redundancy within the system, effective antagonists are in development and undergoing clinical trials, for example, maraviroc, for use in HIV treatment. Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection in infants, with global annual infection estimated at 64 million people. Current treatment is purely supportive, with no effective vaccine available. RSV pathology is partly due to excessive airway inflammation. Evidence is growing for a key role for chemokine receptors. Receptor blockade may therefore provide a feasible therapeutic option to inhibit RSV-induced inflammation and thereby reduce disease severity. |
| doi_str_mv | 10.1586/14787210.5.3.415 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_921303213</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A223971971</galeid><sourcerecordid>A223971971</sourcerecordid><originalsourceid>FETCH-LOGICAL-c527t-69929f5c1f29831ac7392a5d5dcfb92d42ed8ebb483c273773eb615c446b8013</originalsourceid><addsrcrecordid>eNp9kk1v1DAQhiMEomXhzglFIFVcssRfcVxO1YovqRKX3i3HmXRdkjiMHVD-fR3tomoRVLZsj-d5xzPWZNlrUm6JqKsPhMta0mSJLdtyIp5k50RyXtSMVU_TObmL1X-WvQjhriwZV4I-z86IFFyKsjrP5t0eBv_DjRByM7Z53IPDHMHCFD2G3I3JCJNDk8wlb10AE-AyNyuJZoI5OptHg7cQ887jCR2W0S7RmT7_5XBeg3Vgo_Pjy-xZZ_oAr477Jrv5_Olm97W4_v7l2-7qurCCylhUSlHVCUs6qmpGjJVMUSNa0dquUbTlFNoamobXzFLJpGTQVERYzqumLgnbZBeHsBP6nzOEqAcXLPS9GcHPQctSVIQqmsD3j4KEClkLVaUsNtnbv9A7P-OYqtCKElaytCTo3QG6NT3oVLaPaOwaU19RypQkaSZq-w8qjRYGZ_0InUv3J4LyILDoQ0Do9IRuMLhoUuq1IfSfhtBCM50aIkneHNOdmwHaB8GxAxLw8QCs7-NgfnvsWx3N0nvs0IzWBc0eCX95ot6D6ePeGoSHb_mv-B41cdZk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>921303213</pqid></control><display><type>article</type><title>Chemokines and their receptors in respiratory disease: a therapeutic target for respiratory syncytial virus infection</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Thomas, Lynette H ; Friedland, Jon S ; Sharland, Mike</creator><creatorcontrib>Thomas, Lynette H ; Friedland, Jon S ; Sharland, Mike</creatorcontrib><description>Cell recruitment is a multistep process orchestrated by chemokines and their receptors. The chemokine/receptor system is central to many inflammatory diseases, making it a key target for therapeutic intervention. Despite complexity and redundancy within the system, effective antagonists are in development and undergoing clinical trials, for example, maraviroc, for use in HIV treatment. Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection in infants, with global annual infection estimated at 64 million people. Current treatment is purely supportive, with no effective vaccine available. RSV pathology is partly due to excessive airway inflammation. Evidence is growing for a key role for chemokine receptors. Receptor blockade may therefore provide a feasible therapeutic option to inhibit RSV-induced inflammation and thereby reduce disease severity.</description><identifier>ISSN: 1478-7210</identifier><identifier>EISSN: 1744-8336</identifier><identifier>DOI: 10.1586/14787210.5.3.415</identifier><identifier>PMID: 17547506</identifier><language>eng</language><publisher>England: Informa Healthcare</publisher><subject>Antagonists ; Chemokine receptors ; Chemokines ; Chemokines - antagonists & inhibitors ; Clinical trials ; Development and progression ; Drug therapy ; Genetic aspects ; GPCR ; Health aspects ; Human immunodeficiency virus ; Humans ; Infants ; Infection ; inflammation ; Inflammatory diseases ; leukocytes ; Ligands ; Models, Immunological ; Receptors, Chemokine - antagonists & inhibitors ; Respiratory syncytial virus ; Respiratory syncytial virus infection ; Respiratory Syncytial Virus Infections - drug therapy ; Respiratory Syncytial Virus Infections - epidemiology ; Respiratory Syncytial Virus Infections - immunology ; Respiratory tract diseases ; Reviews ; Signal Transduction ; Therapeutic applications ; Vaccines</subject><ispartof>Expert review of anti-infective therapy, 2007-06, Vol.5 (3), p.415-425</ispartof><rights>Future Drugs Ltd 2007</rights><rights>COPYRIGHT 2007 Taylor & Francis Group LLC</rights><rights>2007 Future Drugs Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c527t-69929f5c1f29831ac7392a5d5dcfb92d42ed8ebb483c273773eb615c446b8013</citedby><cites>FETCH-LOGICAL-c527t-69929f5c1f29831ac7392a5d5dcfb92d42ed8ebb483c273773eb615c446b8013</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17547506$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Thomas, Lynette H</creatorcontrib><creatorcontrib>Friedland, Jon S</creatorcontrib><creatorcontrib>Sharland, Mike</creatorcontrib><title>Chemokines and their receptors in respiratory disease: a therapeutic target for respiratory syncytial virus infection</title><title>Expert review of anti-infective therapy</title><addtitle>Expert Rev Anti Infect Ther</addtitle><description>Cell recruitment is a multistep process orchestrated by chemokines and their receptors. The chemokine/receptor system is central to many inflammatory diseases, making it a key target for therapeutic intervention. Despite complexity and redundancy within the system, effective antagonists are in development and undergoing clinical trials, for example, maraviroc, for use in HIV treatment. Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection in infants, with global annual infection estimated at 64 million people. Current treatment is purely supportive, with no effective vaccine available. RSV pathology is partly due to excessive airway inflammation. Evidence is growing for a key role for chemokine receptors. Receptor blockade may therefore provide a feasible therapeutic option to inhibit RSV-induced inflammation and thereby reduce disease severity.</description><subject>Antagonists</subject><subject>Chemokine receptors</subject><subject>Chemokines</subject><subject>Chemokines - antagonists & inhibitors</subject><subject>Clinical trials</subject><subject>Development and progression</subject><subject>Drug therapy</subject><subject>Genetic aspects</subject><subject>GPCR</subject><subject>Health aspects</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Infants</subject><subject>Infection</subject><subject>inflammation</subject><subject>Inflammatory diseases</subject><subject>leukocytes</subject><subject>Ligands</subject><subject>Models, Immunological</subject><subject>Receptors, Chemokine - antagonists & inhibitors</subject><subject>Respiratory syncytial virus</subject><subject>Respiratory syncytial virus infection</subject><subject>Respiratory Syncytial Virus Infections - drug therapy</subject><subject>Respiratory Syncytial Virus Infections - epidemiology</subject><subject>Respiratory Syncytial Virus Infections - immunology</subject><subject>Respiratory tract diseases</subject><subject>Reviews</subject><subject>Signal Transduction</subject><subject>Therapeutic applications</subject><subject>Vaccines</subject><issn>1478-7210</issn><issn>1744-8336</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kk1v1DAQhiMEomXhzglFIFVcssRfcVxO1YovqRKX3i3HmXRdkjiMHVD-fR3tomoRVLZsj-d5xzPWZNlrUm6JqKsPhMta0mSJLdtyIp5k50RyXtSMVU_TObmL1X-WvQjhriwZV4I-z86IFFyKsjrP5t0eBv_DjRByM7Z53IPDHMHCFD2G3I3JCJNDk8wlb10AE-AyNyuJZoI5OptHg7cQ887jCR2W0S7RmT7_5XBeg3Vgo_Pjy-xZZ_oAr477Jrv5_Olm97W4_v7l2-7qurCCylhUSlHVCUs6qmpGjJVMUSNa0dquUbTlFNoamobXzFLJpGTQVERYzqumLgnbZBeHsBP6nzOEqAcXLPS9GcHPQctSVIQqmsD3j4KEClkLVaUsNtnbv9A7P-OYqtCKElaytCTo3QG6NT3oVLaPaOwaU19RypQkaSZq-w8qjRYGZ_0InUv3J4LyILDoQ0Do9IRuMLhoUuq1IfSfhtBCM50aIkneHNOdmwHaB8GxAxLw8QCs7-NgfnvsWx3N0nvs0IzWBc0eCX95ot6D6ePeGoSHb_mv-B41cdZk</recordid><startdate>200706</startdate><enddate>200706</enddate><creator>Thomas, Lynette H</creator><creator>Friedland, Jon S</creator><creator>Sharland, Mike</creator><general>Informa Healthcare</general><general>Taylor & Francis</general><general>Taylor & Francis Group LLC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>200706</creationdate><title>Chemokines and their receptors in respiratory disease: a therapeutic target for respiratory syncytial virus infection</title><author>Thomas, Lynette H ; Friedland, Jon S ; Sharland, Mike</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c527t-69929f5c1f29831ac7392a5d5dcfb92d42ed8ebb483c273773eb615c446b8013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Antagonists</topic><topic>Chemokine receptors</topic><topic>Chemokines</topic><topic>Chemokines - antagonists & inhibitors</topic><topic>Clinical trials</topic><topic>Development and progression</topic><topic>Drug therapy</topic><topic>Genetic aspects</topic><topic>GPCR</topic><topic>Health aspects</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Infants</topic><topic>Infection</topic><topic>inflammation</topic><topic>Inflammatory diseases</topic><topic>leukocytes</topic><topic>Ligands</topic><topic>Models, Immunological</topic><topic>Receptors, Chemokine - antagonists & inhibitors</topic><topic>Respiratory syncytial virus</topic><topic>Respiratory syncytial virus infection</topic><topic>Respiratory Syncytial Virus Infections - drug therapy</topic><topic>Respiratory Syncytial Virus Infections - epidemiology</topic><topic>Respiratory Syncytial Virus Infections - immunology</topic><topic>Respiratory tract diseases</topic><topic>Reviews</topic><topic>Signal Transduction</topic><topic>Therapeutic applications</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Thomas, Lynette H</creatorcontrib><creatorcontrib>Friedland, Jon S</creatorcontrib><creatorcontrib>Sharland, Mike</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Expert review of anti-infective therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Thomas, Lynette H</au><au>Friedland, Jon S</au><au>Sharland, Mike</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chemokines and their receptors in respiratory disease: a therapeutic target for respiratory syncytial virus infection</atitle><jtitle>Expert review of anti-infective therapy</jtitle><addtitle>Expert Rev Anti Infect Ther</addtitle><date>2007-06</date><risdate>2007</risdate><volume>5</volume><issue>3</issue><spage>415</spage><epage>425</epage><pages>415-425</pages><issn>1478-7210</issn><eissn>1744-8336</eissn><abstract>Cell recruitment is a multistep process orchestrated by chemokines and their receptors. The chemokine/receptor system is central to many inflammatory diseases, making it a key target for therapeutic intervention. Despite complexity and redundancy within the system, effective antagonists are in development and undergoing clinical trials, for example, maraviroc, for use in HIV treatment. Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection in infants, with global annual infection estimated at 64 million people. Current treatment is purely supportive, with no effective vaccine available. RSV pathology is partly due to excessive airway inflammation. Evidence is growing for a key role for chemokine receptors. Receptor blockade may therefore provide a feasible therapeutic option to inhibit RSV-induced inflammation and thereby reduce disease severity.</abstract><cop>England</cop><pub>Informa Healthcare</pub><pmid>17547506</pmid><doi>10.1586/14787210.5.3.415</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1478-7210 |
| ispartof | Expert review of anti-infective therapy, 2007-06, Vol.5 (3), p.415-425 |
| issn | 1478-7210 1744-8336 |
| language | eng |
| recordid | cdi_proquest_journals_921303213 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Antagonists Chemokine receptors Chemokines Chemokines - antagonists & inhibitors Clinical trials Development and progression Drug therapy Genetic aspects GPCR Health aspects Human immunodeficiency virus Humans Infants Infection inflammation Inflammatory diseases leukocytes Ligands Models, Immunological Receptors, Chemokine - antagonists & inhibitors Respiratory syncytial virus Respiratory syncytial virus infection Respiratory Syncytial Virus Infections - drug therapy Respiratory Syncytial Virus Infections - epidemiology Respiratory Syncytial Virus Infections - immunology Respiratory tract diseases Reviews Signal Transduction Therapeutic applications Vaccines |
| title | Chemokines and their receptors in respiratory disease: a therapeutic target for respiratory syncytial virus infection |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T05%3A36%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chemokines%20and%20their%20receptors%20in%20respiratory%20disease:%20a%20therapeutic%20target%20for%20respiratory%20syncytial%20virus%20infection&rft.jtitle=Expert%20review%20of%20anti-infective%20therapy&rft.au=Thomas,%20Lynette%20H&rft.date=2007-06&rft.volume=5&rft.issue=3&rft.spage=415&rft.epage=425&rft.pages=415-425&rft.issn=1478-7210&rft.eissn=1744-8336&rft_id=info:doi/10.1586/14787210.5.3.415&rft_dat=%3Cgale_proqu%3EA223971971%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=921303213&rft_id=info:pmid/17547506&rft_galeid=A223971971&rfr_iscdi=true |